WO2020192637A1 - 固体形式的brd4抑制剂化合物及其制备方法与应用 - Google Patents
固体形式的brd4抑制剂化合物及其制备方法与应用 Download PDFInfo
- Publication number
- WO2020192637A1 WO2020192637A1 PCT/CN2020/080741 CN2020080741W WO2020192637A1 WO 2020192637 A1 WO2020192637 A1 WO 2020192637A1 CN 2020080741 W CN2020080741 W CN 2020080741W WO 2020192637 A1 WO2020192637 A1 WO 2020192637A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- alkyl
- compound represented
- solid form
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention relates to a solid form, crystal form and preparation method of a compound represented by formula (I) as a small molecule BRD4 inhibitor, and to its application in the preparation of drugs for treating BRD4-related diseases.
- Histone acetylation can regulate gene transcription and chromosome structure, and play an important role in epigenetics.
- BET (bromodomain and extra-terminal domain) protein as the "reader" of histone acetylation recognition genes, can specifically interact with acetylation.
- the modified lysine binds and recruits other transcription factors, forms a mediator complex by participating in protein-protein interactions, phosphorylates RNA polymerase, and activates downstream genes such as c-Myc for gene transcription regulation.
- Cancer cell proliferation is highly dependent on specific genes (such as c-Myc), and the enhancement of specific gene expression plays an important role in cancer cell proliferation. Studies have shown that the excessive dependence of tumor cells on specific genes makes them very sensitive to BET inhibitors. The presence of BET inhibitors prevents the binding of BET protein to the acetylated lysine of histones, thereby blocking the expression of Myc by transcription factors and inhibiting tumor growth.
- the BET protein family contains 4 members: BRD2, BRD3, BRD4 and BRDT. Each member includes two N-terminal tandem (BD1 and BD2), an extra terminal group (ET), and several groups of conserved regions (A , B, SEED region) and a C-terminal region (CTM). Among them, the most widely studied is BRD4.
- lymphoma such as acute myeloid lymphoma, etc.
- leukemia such as acute lymphoblastic leukemia, etc.
- myeloma such as various myeloma, etc.
- solid tumors such as neurocytoma, glioma, breast cancer (such as triple-negative breast cancer, etc.), gastrointestinal tumors (such as colorectal cancer, etc.) and prostate cancer are all related to the overexpression of BRD4, but there is no Drugs targeting BRD4 were launched.
- the present invention provides a compound represented by formula (I) in solid form,
- the aforementioned solid form is a crystalline form.
- the above crystalline form is the crystal form A of the compound of formula (I), and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 7.03 ⁇ 0.2°, 11.28 ⁇ 0.2°, 14.00 ⁇ 0.2 °.
- the X-ray powder diffraction pattern of the above-mentioned crystal form A has characteristic diffraction peaks at the following 2 ⁇ angles: 7.03 ⁇ 0.2°, 11.28 ⁇ 0.2°, 20.07 ⁇ 0.2°.
- the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2 ⁇ angles: 7.03 ⁇ 0.2°, 19.48 ⁇ 0.2°, 20.07 ⁇ 0.2°, 26.05 ⁇ 0.2°.
- the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2 ⁇ angles: 7.03 ⁇ 0.2°, 11.28 ⁇ 0.2°, 17.31 ⁇ 0.2°, 19.48 ⁇ 0.2°, 20.07 ⁇ 0.2°, 26.05 ⁇ 0.2°.
- the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2 ⁇ angles: 7.03 ⁇ 0.2°, 11.28 ⁇ 0.2°, 14.00 ⁇ 0.2°, 15.11 ⁇ 0.2°, 17.31 ⁇ 0.2°, 19.48 ⁇ 0.2°, 20.07 ⁇ 0.2°, 22.86 ⁇ 0.2°.
- the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2 ⁇ angles: 7.03 ⁇ 0.2°, 11.28 ⁇ 0.2°, 14.00 ⁇ 0.2°, 15.11 ⁇ 0.2°, 17.31 ⁇ 0.2°, 19.48 ⁇ 0.2°, 20.07 ⁇ 0.2°, 26.05 ⁇ 0.2°.
- the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2 ⁇ angles: 7.03 ⁇ 0.2°, 11.28 ⁇ 0.2°, 12.39 ⁇ 0.2°, 14.00 ⁇ 0.2°, 15.11 ⁇ 0.2°, 17.31 ⁇ 0.2°, 19.48 ⁇ 0.2°, 20.07 ⁇ 0.2°, 22.86 ⁇ 0.2°, 26.05 ⁇ 0.2°.
- the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2 ⁇ angles: 7.03 ⁇ 0.2°, 11.28 ⁇ 0.2°, 12.39 ⁇ 0.2°, 14.00 ⁇ 0.2°, 14.87 ⁇ 0.2°, 15.11 ⁇ 0.2°, 17.31 ⁇ 0.2°, 19.48 ⁇ 0.2°, 20.07 ⁇ 0.2°, 22.86 ⁇ 0.2°.
- the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2 ⁇ angles: 7.03 ⁇ 0.2°, 11.28 ⁇ 0.2°, 12.39 ⁇ 0.2°, 14.00 ⁇ 0.2°, 14.87 ⁇ 0.2°, 15.11 ⁇ 0.2°, 17.31 ⁇ 0.2°, 19.48 ⁇ 0.2°, 20.07 ⁇ 0.2°, 22.86 ⁇ 0.2°, 26.05 ⁇ 0.2°.
- the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2 ⁇ angles: 7.03 ⁇ 0.2°, 11.28 ⁇ 0.2°, 12.39 ⁇ 0.2°, 14.00 ⁇ 0.2°, 14.87 ⁇ 0.2°, 15.11 ⁇ 0.2°, 17.31 ⁇ 0.2°, 17.68 ⁇ 0.2°, 19.48 ⁇ 0.2°, 20.07 ⁇ 0.2°, 22.86 ⁇ 0.2°.
- the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2 ⁇ angles: 7.03 ⁇ 0.2°, 11.28 ⁇ 0.2°, 12.39 ⁇ 0.2°, 14.00 ⁇ 0.2°, 14.87 ⁇ 0.2°, 15.11 ⁇ 0.2°, 17.31 ⁇ 0.2°, 17.68 ⁇ 0.2°, 19.48 ⁇ 0.2°, 20.07 ⁇ 0.2°, 22.86 ⁇ 0.2°, 26.05 ⁇ 0.2°.
- the XRPD pattern of the above crystal form A is basically as shown in FIG. 1.
- the XRPD pattern analysis data of the above-mentioned crystal form A is shown in Table 1:
- the differential scanning calorimetry curve of the above-mentioned crystal form A has an endothermic peak starting point at 289.22 ⁇ 3°C.
- the DSC spectrum of the above-mentioned crystal form A is basically as shown in FIG. 2.
- thermogravimetric analysis curve of the above crystal form A has a weight loss of 1.626% at 300.00 ⁇ 3°C.
- the TGA pattern of the above crystal form A is basically as shown in FIG. 3.
- the above crystalline form is the B crystal form of the compound of formula (I), and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 5.50 ⁇ 0.2°, 8.36 ⁇ 0.2°, 11.87 ⁇ 0.2 °.
- the X-ray powder diffraction pattern of the above-mentioned crystal form B has characteristic diffraction peaks at the following 2 ⁇ angles: 5.50 ⁇ 0.2°, 8.36 ⁇ 0.2°, 12.66 ⁇ 0.2°.
- the X-ray powder diffraction pattern of the above-mentioned crystal form B has characteristic diffraction peaks at the following 2 ⁇ angles: 5.50 ⁇ 0.2°, 8.36 ⁇ 0.2°, 11.87 ⁇ 0.2°, 12.39 ⁇ 0.2°, 12.66 ⁇ 0.2°, 15.11 ⁇ 0.2°, 17.35 ⁇ 0.2°, 18.70 ⁇ 0.2°.
- the XRPD pattern of the above-mentioned crystal form B is basically as shown in FIG. 4.
- the XRPD pattern analysis data of the above-mentioned crystal form B is shown in Table 2.
- the present invention also provides a method for preparing the compound represented by formula (I) in the above solid form, wherein the solid form is crystal form A and includes:
- the separation in step (2) is centrifugation or filtration.
- the separation in step (2) is centrifugation.
- a single solvent for C 1-4 alkyl, C 1-4 alkyl-CN, C 1-4 alkyl-OH or C 1-4 alkyl C( O) C 1-4 alkyl.
- the single solvent is methyl tert-butyl ether, ethyl acetate, acetonitrile, ethanol, acetone, methanol or methyl ethyl ketone.
- the volume ratio of C 1-4 alkyl and water is 1-5:1, preferably 2:1; or in the mixed solvent composed of C 1-4 alkyl-OH and water, the C The volume ratio of 1-4 alkyl-OH to water is 1-5:1, preferably 3:1.
- the mixed solvent is a mixed solvent composed of acetone and water, or ethanol and water.
- the mixed solvent is acetone-water with a volume ratio of 2:1, or a mixed solvent composed of ethanol-water with a volume ratio of 3:1.
- C 1-4 alkyl refers to any straight or branched chain group containing 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, Isobutyl, tert-butyl, etc.
- each "C 1-4 alkyl group” may be the same or different.
- the weight-volume ratio of the compound to the solvent is 1g:5-15mL, or 1g:5-12mL, or 1g:5-10mL.
- the stirring temperature is 25°C to 45°C.
- the stirring time is 12 hours to 50 hours, or 12 hours to 48 hours, or 12 hours to 24 hours.
- the present invention also provides a method for preparing the compound represented by formula (I) in the above solid form, wherein the solid form is crystal form B, including:
- the separation in step (2) is centrifugation or filtration.
- the separation in step (2) is centrifugation.
- the solvent is selected from tetrahydrofuran.
- the weight-volume ratio of the compound to the solvent is 1 g: 5-10 mL.
- the stirring temperature is 25°C to 45°C.
- the stirring time is 12 hours to 50 hours, or 12 hours to 48 hours, or 12 hours to 24 hours.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the above-mentioned compound of formula (I) in solid form or any two or more crystalline mixtures.
- the present invention also provides the use of the compound represented by the formula (I) in the solid form or the pharmaceutical composition in the preparation of a medicine for treating BRD4-related disorders.
- the above-mentioned application is characterized in that the BRD4-related disorders include tumor diseases.
- the above application is characterized in that the tumor diseases include hematological tumors and advanced solid tumors, wherein hematological tumors include leukemia, lymphoma and myeloma, and advanced solid tumors include neurocytoma, glioma Tumors, breast cancer, gastrointestinal tumors and prostate cancer; preferably, the leukemia is acute lymphoblastic leukemia, or the lymphoma is acute myeloid lymphoma, or the breast cancer is triple-negative breast cancer, or the gastrointestinal tumor is colorectal cancer .
- the present invention also relates to the compound represented by formula (I) in the above solid form or the above pharmaceutical composition, which is used to treat BRD4-related disorders.
- the compound represented by formula (I) in the above solid form or the above pharmaceutical composition wherein the tumor disease includes hematological tumors and advanced solid tumors, wherein the hematological tumors include leukemia, lymphoma and bone marrow Advanced solid tumors include neurocytoma, glioma, breast cancer, gastrointestinal tumors and prostate cancer; preferably, the leukemia is acute lymphoblastic leukemia, or the lymphoma is acute myeloid lymphoma, or breast cancer is three Negative breast cancer, or gastrointestinal tumor is colorectal cancer.
- the present invention also relates to a method for treating a condition of a patient by administering the compound represented by the formula (I) or the above-mentioned pharmaceutical composition in the solid form to the patient, and the condition of the patient is a BRD4-related condition.
- the above-mentioned method of treating a patient's condition, wherein the BRD4-related condition includes a tumor disease includes a tumor disease.
- the above-mentioned method for treating a patient’s condition wherein the tumor disease includes hematological tumors and advanced solid tumors, wherein hematological tumors include leukemia, lymphoma and myeloma, and advanced solid tumors include neurocytoma , Glioma, breast cancer, gastrointestinal tumors and prostate cancer; preferably, the leukemia is acute lymphoblastic leukemia, or the lymphoma is acute myeloid lymphoma, or the breast cancer is triple-negative breast cancer, or the gastrointestinal tumor is Colorectal cancer.
- the aforementioned "patient” includes all members of the animal kingdom, including but not limited to mammals (for example, mice, rats, cats, monkeys, dogs, horses, pigs, etc.) and humans.
- substantially as shown in the figure refers to at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least in the X-ray powder diffraction pattern or DSC pattern or TGA pattern 95%, or at least 99% of the peaks are shown in the graph.
- the intermediate compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by combining them with other chemical synthesis methods, and those skilled in the art.
- Well-known equivalent alternatives, preferred implementations include but are not limited to the embodiments of the present invention.
- the solvent used in the present invention is commercially available.
- the present invention uses the following abbreviations: DCM stands for dichloromethane; DMF stands for N,N-dimethylformamide; DMSO stands for dimethyl sulfoxide; EtOH stands for ethanol; MeOH stands for methanol; TFA stands for trifluoroacetic acid; TsOH stands for P-toluenesulfonic acid; mp represents melting point; EtSO 3 H represents ethanesulfonic acid; MeSO 3 H represents methanesulfonic acid; ATP represents adenosine triphosphate; HEPES represents 4-hydroxyethylpiperazine ethanesulfonic acid; EGTA represents ethylene glycol bis(2 -Aminoethyl ether) tetraacetic acid; MgCl 2 stands for magnesium dichloride; MnCl 2 stands for manganese dichloride; DTT stands for dithiothreitol.
- the crystal form of the compound of formula (I) mentioned in the present invention has good stability and is easy to prepare medicine; the crystal form of the present invention shows excellent activity on BRD4, has good pharmacokinetic properties and oral absorption rate, has high activity, It has good metabolic stability, good solubility, and is suitable for oral administration. It can provide more effective treatment for diseases caused by abnormal expression of BRD4.
- Test method Approximately 10-20mg sample is used for XRPD detection.
- Tube voltage 40kV
- tube current 40mA
- Test method Take a sample (0.5 ⁇ 1mg) and place it in a DSC aluminum pan for testing. Under the condition of 50mL/min N 2 and at a heating rate of 10°C/min, heat the sample from 30°C to 300°C.
- Test method Take a sample (2 ⁇ 5mg) and place it in a TGA platinum pot for testing. Under the condition of 25mL/min N 2 and at a heating rate of 10°C/min, heat the sample from room temperature to 20% weight loss.
- Test conditions Take samples (10-20mg) and place them in the DVS sample pan for testing.
- ⁇ W% means the moisture gain of the test product at 25 ⁇ 1°C and 80 ⁇ 2%RH.
- Figure 1 is an XRPD spectrum of Cu-K ⁇ radiation of the crystal form of compound A of formula (I).
- Figure 2 is the DSC spectrum of the crystal form of compound A of formula (I).
- Figure 3 is the TGA spectrum of the crystal form of compound A of formula (I).
- Figure 4 is an XRPD spectrum of Cu-K ⁇ radiation of the crystal form of compound B of formula (I).
- Figure 5 is the DVS isotherm of the crystal form of compound A of formula (I).
- step 1
- Phosphorus pentasulfide (17.07g, 76.79mmol, 8.17mL, 3.60eq) was added to the constantly stirring turbid solution of sodium carbonate (4.07g, 38.39mmol, 1.80eq) in 1,2-dichloroethane (200.00ml), in After stirring for 1 hour at 20°C, compound 1-6 (6.50 g, 21.33 mmol, 1.00 eq) was added, and the resulting turbid liquid was reacted at 65°C for 5 hours. The reaction was cooled to 20°C and filtered.
- the filter cake was dissolved with ethyl acetate (2L) and washed with saturated brine (500 mL), dried over sodium sulfate, filtered and spin-dried.
- reaction solution was quenched with saturated NH 4 Cl solution (50 mL), extracted with ethyl acetate (100 mL) and washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and spin-dried.
- the crude compound was purified by a fast column device, and the obtained compound was separated by SFC to obtain compound 1-10 (basic-EtOH, column: AS (250mm ⁇ 30mm, 5 ⁇ m), mobile phase B: 30%, flow rate (mL/min) ):55)([ ⁇ ] 25 D +54(C 0.6,CHCl 3 )).
- Trifluoroacetic acid (3.85g, 33.77mmol, 2.5mL, 18.30eq) was added to compound 3 (0.46g, 1.85mmol, 1 eq) in anhydrous dichloromethane (20ml), after adding, react at 20°C 12 hours. Wash the reaction solution with water (20 mL), adjust the pH of the aqueous phase to 7 with saturated sodium bicarbonate solution, and extract the aqueous phase with dichloromethane (10 mL ⁇ 2). The combined organic phases are dried with anhydrous sodium sulfate and filtered. Spin dry. The obtained compound 4 was directly used in the next reaction without further purification. LCMS (ESI) m/z: 149.8 (M+1).
- LCMS (ESI) m/z: 532.1 (M+1).
- Test conditions Point in time Exterior Crystal form (XRPD) content(%) Total impurities (%) - 0 days
- the compound dilution was done by Echo, and it was diluted by 3 times to 10 concentrations: 20000, 6666.67, 2222.22, 740.74, 246.91, 82.305, 27.435, 9.145, 3.048, 1.016nM.
- test buffer solution 1 ⁇ assay buffer (test buffer solution) to configure the "solution A” (protein solution), “solution B” (peptide solution), and “solution C” (test reagent solution) used in the experiment, and make each The components form a 3X solution in the experimental reaction system, and the amount of solutions A, B, and C must be sufficient for this round of experiments.
- the experiment board is the board containing the compound gradient concentration and the corresponding DMSO solution prepared by ECHO before the experiment:
- the compound of formula (I) has a significant inhibitory effect on BRD4-BD1 and BRD4-BD2.
- Human breast cancer MDA-MB-231_luc cells are cultured in a monolayer in vitro with RPMI-1640 medium (supplier: Gibco; article number: 22400-089; production lot number: 4868546) with 10% fetal bovine serum, 100U/mL Penicillin and 100 ⁇ g/mL streptomycin were cultured at 37°C with 5% CO 2 .
- RPMI-1640 medium supplier: Gibco; article number: 22400-089; production lot number: 4868546
- 10% fetal bovine serum 100U/mL Penicillin and 100 ⁇ g/mL streptomycin were cultured at 37°C with 5% CO 2 .
- pancreatin-EDTA for routine digestion and passage twice a week.
- the cells are in the exponential growth phase, the cells are collected, counted, and seeded.
- the experimental index is to investigate whether the tumor growth is inhibited, delayed or cured.
- the tumor diameter was measured with vernier calipers twice a week.
- TGI (%) reflects the tumor growth inhibition rate.
- TGI(%) [(1-(Average tumor volume at the end of a certain treatment group-average tumor volume at the beginning of the treatment group))/(Average tumor at the end of treatment in the vehicle control group Volume-The average tumor volume at the start of treatment in the vehicle control group)] ⁇ 100%.
- T weight and C weight represent the tumor weight of the administration group and the vehicle control group, respectively.
- the preparation method of the test substance is the same as Table 6, and the animal grouping and dosing schedule are the same as Table 7.
- Human prostate cancer PC-3 cells were cultured in monolayer in vitro with F-12K medium (supplier: Gibco; article number: 21127-022; production lot number: 1868870) with 10% fetal bovine serum and 100U/mL penicillin Incubate with 100 ⁇ g/mL streptomycin at 37°C with 5% CO 2 . Use pancreatin-EDTA for routine digestion and passage twice a week. When the cells are in the exponential growth phase, the cells are collected, counted, and seeded.
- Mouse colon cancer MC38 cells (Heyuan Biotechnology Co., Ltd.) were cultured in a monolayer in vitro with 10% fetal bovine serum in DMEM medium (Gibco, item number: 12100), 37°C and 5% CO 2 in an incubator to cultivate. Use 0.25% pancreatin-EDTA for routine digestion and passage. When the cells are in the exponential growth phase and the saturation is 80% to 90%, the cells are collected, counted, and inoculated.
- 0.1 mL of 2 ⁇ 10 5 MC38 cells were subcutaneously inoculated on the right back of each mouse, and when the average tumor volume reached ⁇ 70 mm 3 , randomized administration was performed according to the tumor volume.
- the tumor diameter was measured with vernier calipers twice a week.
- the anti-tumor efficacy of the compound is evaluated by TGI (%) or relative tumor growth rate T/C (%).
- Relative tumor proliferation rate T/C (%) T RTV /C RTV ⁇ 100% (T RTV : RTV in the treatment group; C RTV : RTV in the negative control group).
- RTV relative tumor volume
- TGI (%) reflects the tumor growth inhibition rate.
- TGI(%) [(1-(Average tumor volume at the end of a certain treatment group-average tumor volume at the beginning of the treatment group))/(Average tumor volume at the end of treatment in the vehicle control group-start treatment in the vehicle control group Average tumor volume at time)] ⁇ 100%.
- T weight and C weight represent the tumor weight of the administration group and the vehicle control group, respectively.
- the statistical analysis was based on the tumor volume and tumor weight at the end of the experiment using SPSS software.
- the comparison between the two groups is analyzed by t-test, and the comparison between three or more groups is analyzed by one-way ANOVA. If the variance is uniform (the F value is not significantly different), the LSD method is used for analysis. If the variance is not uniform (F Values are significantly different), using Games-Howell method to test. p ⁇ 0.05 considered a significant difference.
- the LC/MS/MS method was used to determine the drug concentration in plasma at different times after intravenous and intragastric administration of the compound of formula (I). Study the pharmacokinetic behavior of the compound of formula (I) in mice, and evaluate its pharmacokinetic characteristics.
- mice 16 healthy adult female Balb/c mice were divided into 4 groups according to the principle of similar body weight, 4 in each group. Animals were purchased from Shanghai Lingchang Biological Technology Co., Ltd. Experimental Animal Co., Ltd., animal production license number: SCXK (Shanghai) 2013-0018
- mice Eight female Balb/c mice were divided into two groups. After an overnight fast, the first group was given intravenous administration with a volume of 2.5 mL/kg and a dose of 1 mg/kg; the second group was given intragastric administration. The administration volume is 5 mL/kg, and the dose is 3 mg/kg. 2. Operation
- the LC/MS/MS method was used to determine the content of the test compound in the mouse plasma after intravenous and intragastric administration.
- the linear range of the method is 2.00-6000nmol/L; plasma samples are analyzed after acetonitrile-precipitated protein treatment.
- the results of the pharmacokinetic parameters are shown in Table 8.
- the compound of formula (I) has high oral exposure, low pharmacokinetic clearance rate and high oral bioavailability.
- the LC/MS/MS method was used to determine the drug concentration in plasma at different times after intravenous and intragastric administration of the compound of formula (I). Study the pharmacokinetic behavior of the compound of formula (I) in rats and evaluate its pharmacokinetic characteristics.
- the LC/MS/MS method was used to determine the content of the test compound in the rat plasma after intravenous and intragastric administration.
- the linear range of the method is 2.00-6000nmol/L; plasma samples are analyzed after acetonitrile-precipitated protein treatment.
- the results of the pharmacokinetic parameters are shown in Table 9.
- the compound of formula (I) has high oral exposure, low pharmacokinetic clearance rate and high oral bioavailability.
- CHO-hERG cells were cultured in a 175cm 2 culture flask. After the cell density grew to 60-80%, the culture medium was removed, washed with 7mL PBS, and then digested with 3mL Detachin.
- the single-cell high-impedance sealing and the whole-cell mode formation process are all automatically completed by the Qpatch instrument.
- the cell is clamped at -80 mV, before giving a 5 second +40 mV depolarization stimulus .
- First give a pre-voltage of -50 mV for 50 milliseconds, then repolarize to -50 mV for 5 seconds, and then return to -80 mV. Apply this voltage stimulus every 15 seconds, record for 2 minutes, give extracellular fluid, record for 5 minutes, then start the dosing process, the compound concentration starts from the lowest test concentration, each test concentration is given for 2.5 minutes, after all the concentrations are given continuously Positive control compound 3 ⁇ M Cisapride. At least 3 cells are tested at each concentration (n ⁇ 3).
- the experimental data is analyzed by XLFit software.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
编号 | 溶剂 | 溶剂量(mL) | 晶型(XRPD) |
1 | 丙酮:水(2:1) | 0.3 | A |
2 | 甲基叔丁基醚 | 0.5 | A |
3 | 乙酸乙酯 | 0.5 | A |
4 | 乙腈 | 0.5 | A |
5 | 乙醇 | 0.5 | A |
6 | 丙酮 | 0.4 | A |
7 | 甲醇 | 0.6 | A |
8 | 甲乙酮 | 0.4 | A |
9 | 乙醇:水(3:1)(3:1) | 0.4 | A |
试验条件 | 时间点 | 外观 | 晶型(XRPD) | 含量(%) | 总杂质(%) |
- | 0天 | 白色粉末 | 晶型A | 98.7 | 0.17 |
40℃/75%RH,密封 | 90天 | 白色粉末 | 晶型A | 99.2 | 0.19 |
25℃/60%RH,密封 | 90天 | 白色粉末 | 晶型A | 99.4 | 0.12 |
化合物 | BRD4(BD1,BD2),IC 50(nM) |
式(I)化合物 | 66,10 |
Claims (12)
- 根据权利要求1所述的固体形式的式(I)所示化合物,其为结晶形式。
- 根据权利要求2所述的固体形式的式(I)所示化合物,其为式(I)化合物的A晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:7.03±0.2°,11.28±0.2°,14.00±0.2°;或者,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:7.03±0.2°,11.28±0.2°,20.07±0.2°;或者,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:7.03±0.2°,19.48±0.2°,20.07±0.2°,26.05±0.2°;或者,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:7.03±0.2°,11.28±0.2°,17.31±0.2°,19.48±0.2°,20.07±0.2°,26.05±0.2°;或者,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:7.03±0.2°,11.28±0.2°,14.00±0.2°,15.11±0.2°,17.31±0.2°,19.48±0.2°,20.07±0.2°,26.05±0.2°;或者,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:7.03±0.2°,11.28±0.2°,12.39±0.2°,14.00±0.2°,15.11±0.2°,17.31±0.2°,19.48±0.2°,20.07±0.2°,22.86±0.2°,26.05±0.2°;或者,其XRPD图谱基本上如图1所示。
- 根据权利要求3所述的固体形式的式(I)所示化合物,其差示扫描量热曲线在289.22±3℃有一个吸热峰的起始点。
- 根据权利要求4所述的固体形式的式(I)所示化合物,其DSC图谱基本上如图2所示。
- 根据权利要求3所述的固体形式的式(I)所示化合物,其热重分析曲线在300.00±3℃处失重达1.626%。
- 根据权利要求6所述的固体形式的式(I)所示化合物,其TGA图谱基本上如图3所示。
- 根据权利要求2所述的固体形式的式(I)所示化合物,其为式(I)化合物的B晶型,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:5.50±0.2°,8.36±0.2°,11.87±0.2°;或者,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:5.50±0.2°,8.36±0.2°,12.66±0.2°;或者,其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:5.50±0.2°,8.36±0.2°,11.87±0.2°,12.39±0.2°,12.66±0.2°,15.11±0.2°,17.35±0.2°,18.70±0.2°;或者,其XRPD图谱基本上如图4所示。
- 一种权利要求3所述的固体形式的式(I)所示化合物的制备方法,包括:(1)将式(I)所示化合物加入溶剂中,使其成混悬液或溶液;优选地,所述溶剂为选自C 1-4烷基-O-C 1-4烷基、C 1-4烷基C(=O)OC 1-4烷基、C 1-4烷基-CN、C 1-4烷基-OH或C 1-4烷基C(=O)C 1-4烷基的单一溶剂;进一步优选地,所述单一溶剂为甲基叔丁基醚、乙酸乙酯、乙腈、乙醇、丙酮、甲醇或甲乙酮;或者,优选地,所述溶剂为C 1-4烷基C(=O)C 1-4烷基和水,或者C 1-4烷基-OH和水组成的混合溶剂;进一步优选地,所述C 1-4烷基C(=O)C 1-4烷基和水组成的混合溶剂中,所述C 1- 4烷基C(=O)C 1-4烷基和水的体积比为1-5:1,优选为2:1;所述C 1-4烷基-OH和水组成的混合溶剂中,所述C 1-4烷基-OH和水的体积比为1-5:1,优选为3:1;进一步优选地,所述混合溶剂为丙酮和水,或者乙醇和水组成的混合溶剂;进一步优选地,所述混合溶剂为体积比为2:1的丙酮-水,或者体积比为3:1的乙醇-水,组成的混合溶剂;或者优选地,化合物与溶剂的重量-体积比为1g:5~15mL,优选为1g:5~12mL;(2)上述混悬液或溶液于恒温混匀仪中,搅拌后分离,干燥,得到式(I)所示化合物的A晶型;优选地,搅拌温度为25℃~45℃;或者优选地,搅拌时间为12小时~50小时,优选为12小时-48小时;或者优选地,步骤(2)中所述分离为离心或过滤;进一步优选地,步骤(2)中所述分离为离心。
- 一种权利要求8所述的固体形式的式(I)所示化合物的制备方法,包括:(1)将式(I)所示化合物加入四氢呋喃中,使其成混悬液或溶液;优选地,化合物与四氢呋喃的重量-体积比为1g:5~10mL;(2)上述混悬液或溶液于恒温混匀仪中,搅拌后分离,干燥,得到式(I)所示化合物的B晶型;优选地,搅拌温度为25℃~45℃;或者优选地,搅拌时间为12小时~50小时,优选为12小时-48小时;或者优选地,步骤(2)中所述分离为离心或过滤;进一步优选地,步骤(2)中所述分离为离心。
- 一种药物组合物,包含权利要求1-8任一项所述的固体形式的式(I)化合物或任意两种或两种以上的结晶混合物。
- 根据权利要求1-8任一项所述的固体形式的式(I)所示化合物或权利要求11所述的药物组合物在制备治疗BRD4相关病症的药物上的应用;优选地,所述BRD4相关病症包括肿瘤疾病;更优选地,所述肿瘤包括血液肿瘤和晚期实体瘤,其中,血液肿瘤包括白血病、淋巴瘤及骨髓瘤,晚期实体瘤包括神经细胞瘤、胶质瘤、乳腺癌、胃肠肿瘤及***癌;进一步优选地,白血病为急性成淋巴细胞性白血病,或者,淋巴瘤为急性骨髓淋巴瘤;进一步优选地,乳腺癌为三阴性乳腺癌,或者,胃肠肿瘤为结直肠癌。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020217034008A KR20210151841A (ko) | 2019-03-22 | 2020-03-23 | 고체 형태의 brd4 억제제 화합물 및 이의 제조 방법 및 이의 용도 |
CA3134071A CA3134071A1 (en) | 2019-03-22 | 2020-03-23 | Brd4 inhibitor compound in solid form and preparation method therefor and use thereof |
EP20776535.5A EP3943498A4 (en) | 2019-03-22 | 2020-03-23 | BRD4 INHIBITOR COMPOUND IN SOLID FORM AND PROCESSES FOR THE PREPARATION AND USE THEREOF |
AU2020248834A AU2020248834B2 (en) | 2019-03-22 | 2020-03-23 | BRD4 inhibitor compound in solid form and preparation method therefor and application thereof |
US17/593,668 US20220185820A1 (en) | 2019-03-22 | 2020-03-23 | Brd4 inhibitor compound in solid form and preparation method therefor and use thereof |
CN202080022188.3A CN113646312B (zh) | 2019-03-22 | 2020-03-23 | 固体形式的brd4抑制剂化合物及其制备方法与应用 |
JP2021558494A JP2022536574A (ja) | 2019-03-22 | 2020-03-23 | 固体形態のbrd4阻害剤化合物およびその調製方法およびその使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910225039.6 | 2019-03-22 | ||
CN201910225039 | 2019-03-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020192637A1 true WO2020192637A1 (zh) | 2020-10-01 |
Family
ID=72610974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/080741 WO2020192637A1 (zh) | 2019-03-22 | 2020-03-23 | 固体形式的brd4抑制剂化合物及其制备方法与应用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220185820A1 (zh) |
EP (1) | EP3943498A4 (zh) |
JP (1) | JP2022536574A (zh) |
KR (1) | KR20210151841A (zh) |
CN (1) | CN113646312B (zh) |
AU (1) | AU2020248834B2 (zh) |
CA (1) | CA3134071A1 (zh) |
WO (1) | WO2020192637A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021180055A1 (zh) * | 2020-03-09 | 2021-09-16 | 石药集团中奇制药技术(石家庄)有限公司 | 一种brd4抑制剂的用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5712274A (en) * | 1993-09-16 | 1998-01-27 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienotriazolodiazepine compounds and their pharmaceutical use |
CN101910182A (zh) * | 2007-12-28 | 2010-12-08 | 田边三菱制药株式会社 | 抗癌剂 |
WO2015018520A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma |
WO2017030814A1 (en) * | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
WO2017223268A1 (en) * | 2016-06-22 | 2017-12-28 | Yale University | COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi) |
WO2019056950A1 (zh) * | 2017-09-22 | 2019-03-28 | 南京明德新药研发股份有限公司 | 噻吩并二氮杂卓衍生物及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102011082013A1 (de) * | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
-
2020
- 2020-03-23 AU AU2020248834A patent/AU2020248834B2/en active Active
- 2020-03-23 WO PCT/CN2020/080741 patent/WO2020192637A1/zh active Application Filing
- 2020-03-23 US US17/593,668 patent/US20220185820A1/en active Pending
- 2020-03-23 JP JP2021558494A patent/JP2022536574A/ja active Pending
- 2020-03-23 EP EP20776535.5A patent/EP3943498A4/en active Pending
- 2020-03-23 CN CN202080022188.3A patent/CN113646312B/zh active Active
- 2020-03-23 CA CA3134071A patent/CA3134071A1/en active Pending
- 2020-03-23 KR KR1020217034008A patent/KR20210151841A/ko active Search and Examination
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5712274A (en) * | 1993-09-16 | 1998-01-27 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienotriazolodiazepine compounds and their pharmaceutical use |
CN101910182A (zh) * | 2007-12-28 | 2010-12-08 | 田边三菱制药株式会社 | 抗癌剂 |
WO2015018520A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma |
WO2017030814A1 (en) * | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
WO2017223268A1 (en) * | 2016-06-22 | 2017-12-28 | Yale University | COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi) |
WO2019056950A1 (zh) * | 2017-09-22 | 2019-03-28 | 南京明德新药研发股份有限公司 | 噻吩并二氮杂卓衍生物及其应用 |
Non-Patent Citations (2)
Title |
---|
"Chinese Pharmacopoeia", vol. IV, 2015, pages: 9001 |
See also references of EP3943498A4 |
Also Published As
Publication number | Publication date |
---|---|
CN113646312B (zh) | 2022-12-06 |
CN113646312A (zh) | 2021-11-12 |
EP3943498A4 (en) | 2023-01-04 |
EP3943498A1 (en) | 2022-01-26 |
US20220185820A1 (en) | 2022-06-16 |
CA3134071A1 (en) | 2020-10-01 |
AU2020248834B2 (en) | 2023-06-29 |
AU2020248834A1 (en) | 2021-10-28 |
KR20210151841A (ko) | 2021-12-14 |
JP2022536574A (ja) | 2022-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018201896B2 (en) | Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor | |
CN104936954A (zh) | 化合物及其使用方法 | |
CA3085498C (en) | Crystal form and salt form of tgf-.beta.ri inhibitor and preparation method therefor | |
WO2020192637A1 (zh) | 固体形式的brd4抑制剂化合物及其制备方法与应用 | |
CN111630047A (zh) | 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途 | |
JP2022518605A (ja) | ジアリールチオヒダントイン化合物結晶 | |
WO2022257965A1 (zh) | 固体形式的周期蛋白依赖性激酶9抑制剂及其用途 | |
AU2017286217B2 (en) | Novel dizocilpine derivatives as peripheral NMDA receptor antagonists | |
US20230123104A1 (en) | Crystal of tricyclic compound acting on crbn protein and preparation method therefor | |
WO2021083380A1 (zh) | Eed抑制剂及其制备方法和用途 | |
RU2793346C1 (ru) | Соединение ингибитора brd4 в твердой форме, способ его получения и применение | |
CN113166121B (zh) | 一种fxr激动剂的固体形式、结晶形式、a晶型及其制备方法和应用 | |
CN117355528B (zh) | 吡咯并三嗪类化合物的盐型、其晶型及其制备方法 | |
WO2021164789A1 (zh) | 一种吡唑并嘧啶类化合物的晶型及其应用 | |
WO2022048685A1 (zh) | 苯并四氢呋喃肟类化合物的晶型及其制备方法 | |
RU2810214C2 (ru) | Кристалл диарилтиогидантоинового соединения | |
WO2020221358A1 (zh) | Wee1抑制剂化合物的晶型及其应用 | |
WO2021139794A1 (zh) | 一种吡咯烷基脲衍生物的晶型及其应用 | |
WO2020224585A1 (zh) | 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法 | |
JP7432739B2 (ja) | アザインドール誘導体の結晶形及びその応用 | |
US20220177453A1 (en) | Crystallization of smac mimic used as iap inhibitor and preparation method thereof | |
CN110117272A (zh) | 细胞周期蛋白依赖性激酶抑制剂的盐及其晶型 | |
EP3468969A1 (en) | Novel dizocilpine derivatives as peripheral nmda receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20776535 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3134071 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021558494 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217034008 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021128472 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2020248834 Country of ref document: AU Date of ref document: 20200323 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020776535 Country of ref document: EP Effective date: 20211022 |